3 results
To determine the feasibility, toxicity and safety of anti-CEA x anti hapten bispecific antibodies (TF2) and Lu-177-labelled di-HSG-DOTA peptide (IMP-288) in patients with advanced colorectal carcinoma.
The first objective is to evaluate the superiority of CHF 5259 pMDI (glycopyrrolate bromide) (50 µg total daily dose) versus placebo in terms of FEV1 AUC0-12h normalised by time on Day 42.Key Secondary objectiveTo evaluate the superiority of CHF…
The primary objective is to determine the optimal pharmacokinetic model of 68Ga-PSMA PET/CT, so 68Ga-PSMA PET/CT results can be quantified in prostate cancer.The secondary objectives are to determine whether the optimal kinetic model of 68Ga-PSMA…